Zobrazeno 1 - 7 of 7 pro vyhledávání: '"Potluri, LB"'
2
Akademický článek
ABL1 kinase plays an important role in spontaneous and chemotherapy-induced genomic instability in multiple myeloma.
Autor: Kumar S; The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; VA Boston Healthcare System, Boston, MA., Talluri S; The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; VA Boston Healthcare System, Boston, MA., Zhao J; The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; VA Boston Healthcare System, Boston, MA., Liao C; The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; VA Boston Healthcare System, Boston, MA., Potluri LB; The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; VA Boston Healthcare System, Boston, MA., Buon L; The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Mu S; The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; VA Boston Healthcare System, Boston, MA., Shi J; The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; VA Boston Healthcare System, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Chakraborty C; The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Tai YT; The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Samur MK; The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Munshi NC; The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; VA Boston Healthcare System, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA., Shammas MA; The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.; VA Boston Healthcare System, Boston, MA.
Publikováno v: Blood [Blood] 2024 Mar 14; Vol. 143 (11), pp. 996-1005.
Zobrazit plný text záznamu
3
Akademický článek
Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival.
Autor: Prabhala R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; VA Boston Healthcare System, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States., Pierceall WE; Bristol Myers Squibb, Summit, NJ, United States., Samur M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Department of Biostatistics, Harvard TH Chan School of Public Health, Boston, MA, United States., Potluri LB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States., Hong K; Bristol Myers Squibb, Summit, NJ, United States., Peluso T; Bristol Myers Squibb, Summit, NJ, United States., Talluri S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States., Wang A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States., Katiki A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States., Vangala SD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States., Buonopane M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States., Bade V; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States., Seah H; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States., Krogman A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States., Derebail S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States., Fulciniti M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States., Lazo SB; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States., Richardson P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States., Anderson K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States., Corre J; Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France., Avet-Loiseau H; Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France., Thakurta A; Bristol Myers Squibb, Summit, NJ, United States.; Oxford Centre for Translational Myeloma Research, Oxford, United Kingdom., Munshi N; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; VA Boston Healthcare System, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States.
Publikováno v: Frontiers in oncology [Front Oncol] 2023 Dec 04; Vol. 13, pp. 1271807. Date of Electronic Publication: 2023 Dec 04 (Print Publication: 2023).
Zobrazit plný text záznamu
4
Akademický článek
Elevated APE1 Dysregulates Homologous Recombination and Cell Cycle Driving Genomic Evolution, Tumorigenesis, and Chemoresistance in Esophageal Adenocarcinoma.
Autor: Kumar S; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts; Hematology and Oncology, Veterans Affairs Boston Healthcare System, West Roxbury, Massachusetts., Zhao J; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts; Hematology and Oncology, Veterans Affairs Boston Healthcare System, West Roxbury, Massachusetts., Talluri S; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts; Hematology and Oncology, Veterans Affairs Boston Healthcare System, West Roxbury, Massachusetts., Buon L; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts., Mu S; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts; Hematology and Oncology, Veterans Affairs Boston Healthcare System, West Roxbury, Massachusetts., Potluri LB; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts; Hematology and Oncology, Veterans Affairs Boston Healthcare System, West Roxbury, Massachusetts., Liao C; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts; Hematology and Oncology, Veterans Affairs Boston Healthcare System, West Roxbury, Massachusetts., Shi J; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts; Hematology and Oncology, Veterans Affairs Boston Healthcare System, West Roxbury, Massachusetts; Department of Medicine, Harvard Medical School, Boston, Massachusetts., Chakraborty C; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts., Gonzalez GB; Hematology and Oncology, Veterans Affairs Boston Healthcare System, West Roxbury, Massachusetts; Department of Medicine, Harvard Medical School, Boston, Massachusetts., Tai YT; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts., Patel J; Department of Medicine, Harvard Medical School, Boston, Massachusetts; Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts., Pal J; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts; Pt. Jawahar Lal Nehru Memorial Medical College, Raipur, Chhattisgarh, India., Mashimo H; Hematology and Oncology, Veterans Affairs Boston Healthcare System, West Roxbury, Massachusetts; Department of Medicine, Harvard Medical School, Boston, Massachusetts., Samur MK; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts., Munshi NC; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts; Hematology and Oncology, Veterans Affairs Boston Healthcare System, West Roxbury, Massachusetts; Department of Medicine, Harvard Medical School, Boston, Massachusetts., Shammas MA; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts; Hematology and Oncology, Veterans Affairs Boston Healthcare System, West Roxbury, Massachusetts. Electronic address: Masood_Shammas@DFCI.Harvard.edu.
Publikováno v: Gastroenterology [Gastroenterology] 2023 Aug; Vol. 165 (2), pp. 357-373. Date of Electronic Publication: 2023 May 12.
Zobrazit plný text záznamu
5
Report
Two primary cancers appeared after discontinuation of nivolumab in the course of treating Hodgkin lymphoma: a case report.
Autor: Potluri LB; Department of Internal Medicine at Detroit Medical Center/Wayne State University, Sinai Grace Hospital, Detroit, MI, USA., Nanjareddy S; Department of Internal Medicine at Detroit Medical Center/Wayne State University, Sinai Grace Hospital, Detroit, MI, USA., Al Sbihi A; Department of Internal Medicine at St. Mary Mercy Hospital, Livonia, MI, USA., Manasrah N; Department of Internal Medicine at Detroit Medical Center/Wayne State University, Sinai Grace Hospital, Detroit, MI, USA., Smith W 4th; Department of Pathology, Detroit Medical Center/Wayne State University, Detroit, MI, USA., Sano D; Department of Oncology, University of Michigan, Ann Arbor, MI, USA.
Publikováno v: AME case reports [AME Case Rep] 2023 Jul 10; Vol. 7, pp. 30. Date of Electronic Publication: 2023 Jul 10 (Print Publication: 2023).
Zobrazit plný text záznamu
6
Akademický článek
Development and validation of a deep transfer learning-based multivariable survival model to predict overall survival in lung cancer.
Autor: Zhu F; Department of Internal Medicine, Detroit Medical Center Sinai Grace Hospital, Detroit, MI, USA.; Department of Thoracic Surgery and Oncology, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China., Zhong R; Department of Thoracic Surgery and Oncology, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China., Li F; Department of Thoracic Surgery and Oncology, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China., Li C; Department of Thoracic Surgery and Oncology, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China., Din N; Department of Internal Medicine, Detroit Medical Center Sinai Grace Hospital, Detroit, MI, USA., Sweidan H; Department of Internal Medicine, Detroit Medical Center Sinai Grace Hospital, Detroit, MI, USA., Potluri LB; Department of Internal Medicine, Detroit Medical Center Sinai Grace Hospital, Detroit, MI, USA., Xiong S; Department of Thoracic Surgery and Oncology, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China., Li J; Department of Thoracic Surgery and Oncology, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China., Cheng B; Department of Thoracic Surgery and Oncology, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China., Chen Z; Department of Thoracic Surgery and Oncology, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China., He J; Department of Thoracic Surgery and Oncology, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China., Liang W; Department of Thoracic Surgery and Oncology, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China., Pan Z; Department of Oncology, Qingdao Municipal Hospital, Qingdao, China.
Publikováno v: Translational lung cancer research [Transl Lung Cancer Res] 2023 Mar 31; Vol. 12 (3), pp. 471-482.
Zobrazit plný text záznamu
7
Akademický článek
Dysregulated APOBEC3G causes DNA damage and promotes genomic instability in multiple myeloma.
Autor: Talluri S; Dana Farber Cancer Institute, Boston, MA, 02115, USA.; Veterans Administration Boston Healthcare System, West Roxbury, MA, 02132, USA., Samur MK; Dana Farber Cancer Institute, Boston, MA, 02115, USA., Buon L; Dana Farber Cancer Institute, Boston, MA, 02115, USA., Kumar S; Dana Farber Cancer Institute, Boston, MA, 02115, USA.; Veterans Administration Boston Healthcare System, West Roxbury, MA, 02132, USA., Potluri LB; Dana Farber Cancer Institute, Boston, MA, 02115, USA.; Veterans Administration Boston Healthcare System, West Roxbury, MA, 02132, USA., Shi J; Dana Farber Cancer Institute, Boston, MA, 02115, USA.; Veterans Administration Boston Healthcare System, West Roxbury, MA, 02132, USA., Prabhala RH; Dana Farber Cancer Institute, Boston, MA, 02115, USA.; Veterans Administration Boston Healthcare System, West Roxbury, MA, 02132, USA.; Harvard Medical School, Boston, MA, 02215, USA., Shammas MA; Dana Farber Cancer Institute, Boston, MA, 02115, USA.; Veterans Administration Boston Healthcare System, West Roxbury, MA, 02132, USA., Munshi NC; Dana Farber Cancer Institute, Boston, MA, 02115, USA. Nikhil_Munshi@DFCI.Harvard.edu.; Veterans Administration Boston Healthcare System, West Roxbury, MA, 02132, USA. Nikhil_Munshi@DFCI.Harvard.edu.; Harvard Medical School, Boston, MA, 02215, USA. Nikhil_Munshi@DFCI.Harvard.edu.
Publikováno v: Blood cancer journal [Blood Cancer J] 2021 Oct 08; Vol. 11 (10), pp. 166. Date of Electronic Publication: 2021 Oct 08.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje